Effects of ex vivo exposure of healthy and chronic kidney disease bone marrow cells to pravastatin or DMEM on longitudinal plasma and urinary variables of chronic kidney disease recipients. (A) Urea. (B) Diuresis. (C) Proteinuria. (D) Creatinine clearance. (E) Nitric oxide (NO) metabolites. (F) Natriuresis. Week 5 represents 1 week before BMC injection. Data presented as mean ± standard deviation. BMC, bone marrow cell; BW, body weight; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium; SNX, subtotal nephrectomy.